P-Tau as prognostic marker in long term follow up for patients with shunted iNPH
Objective: Diagnosis of idiopathic Normal Pressure Hydrocephalus (iNPH) relies solely on clinical and radiological criteria while, unlike other neurological diseases, the analysis of cerebrospinal fluid markers is not used in clinical practice. Nevertheless, the overlapping of neurodegenerative diseases affects the long-term shunt efficacy and this occurrence should be detected before surgery. Therefore, we performed this study in order to assess the correlation between pre-surgical levels of CSF Beta Amyloid protein, Total Tau protein and Phospho-Tau protein with long-term clinical outcome. Methods: Between March 2012 and May 2016 we prospective evaluated all patients with iNPH according to guidelines criteria and we analysed CSF concentration of these proteins before and during surgery. Two years after surgery we evaluated iNPH score for all patients, grouping them in shunt responders and non-responders. Results: A total of 117 patients were included: Tap Test non-responders were 58 and at two years we had 35 shunt responders and 15 shunt non-responders. We found a significative difference between shunt-responders and shunt non-responders for pre surgical T-Tau (p: 0.02) and for P-Tau (p: 0.01). All the proteins were significantly associated with clinical outcome after surgery with different cut-off values; in particular, having a 'low' value of T-Tau, P-Tau and Aβ1-42 resulted in favourable outcome after surgery. Conclusions: Low level of P-Tau is a useful CSF biochemical prognostic factor for good clinical outcome at least two years after shunt; meanwhile a lower Aβ1-42 might suggest that the pathophysiology of iNPH could have something in common with other neurodegenerative diseases of the elderly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Neurological research - 43(2021), 1 vom: 20. Jan., Seite 78-85 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Migliorati, Karol [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alzheimer disease |
|---|
| Anmerkungen: |
Date Completed 13.10.2021 Date Revised 13.10.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/01616412.2020.1831300 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316290815 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316290815 | ||
| 003 | DE-627 | ||
| 005 | 20231225160751.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/01616412.2020.1831300 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316290815 | ||
| 035 | |a (NLM)33059546 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Migliorati, Karol |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a P-Tau as prognostic marker in long term follow up for patients with shunted iNPH |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.10.2021 | ||
| 500 | |a Date Revised 13.10.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: Diagnosis of idiopathic Normal Pressure Hydrocephalus (iNPH) relies solely on clinical and radiological criteria while, unlike other neurological diseases, the analysis of cerebrospinal fluid markers is not used in clinical practice. Nevertheless, the overlapping of neurodegenerative diseases affects the long-term shunt efficacy and this occurrence should be detected before surgery. Therefore, we performed this study in order to assess the correlation between pre-surgical levels of CSF Beta Amyloid protein, Total Tau protein and Phospho-Tau protein with long-term clinical outcome. Methods: Between March 2012 and May 2016 we prospective evaluated all patients with iNPH according to guidelines criteria and we analysed CSF concentration of these proteins before and during surgery. Two years after surgery we evaluated iNPH score for all patients, grouping them in shunt responders and non-responders. Results: A total of 117 patients were included: Tap Test non-responders were 58 and at two years we had 35 shunt responders and 15 shunt non-responders. We found a significative difference between shunt-responders and shunt non-responders for pre surgical T-Tau (p: 0.02) and for P-Tau (p: 0.01). All the proteins were significantly associated with clinical outcome after surgery with different cut-off values; in particular, having a 'low' value of T-Tau, P-Tau and Aβ1-42 resulted in favourable outcome after surgery. Conclusions: Low level of P-Tau is a useful CSF biochemical prognostic factor for good clinical outcome at least two years after shunt; meanwhile a lower Aβ1-42 might suggest that the pathophysiology of iNPH could have something in common with other neurodegenerative diseases of the elderly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CSF protein | |
| 650 | 4 | |a Normal pressure hydrocephalus | |
| 650 | 4 | |a alzheimer disease | |
| 650 | 4 | |a neurodegenerative disease | |
| 650 | 4 | |a shunt | |
| 650 | 7 | |a Amyloid beta-Peptides |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a MAPT protein, human |2 NLM | |
| 650 | 7 | |a tau Proteins |2 NLM | |
| 700 | 1 | |a Panciani, Pier Paolo |e verfasserin |4 aut | |
| 700 | 1 | |a Pertichetti, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Borroni, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Archetti, Silvana |e verfasserin |4 aut | |
| 700 | 1 | |a Rozzini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Padovani, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Terzi, Lodovico |e verfasserin |4 aut | |
| 700 | 1 | |a Bruscella, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Fontanella, Marco Maria |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurological research |d 1987 |g 43(2021), 1 vom: 20. Jan., Seite 78-85 |w (DE-627)NLM000961604 |x 1743-1328 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:2021 |g number:1 |g day:20 |g month:01 |g pages:78-85 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/01616412.2020.1831300 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 2021 |e 1 |b 20 |c 01 |h 78-85 | ||